Peringatan Keamanan

There is no information regarding the acute toxicity (LD50) and overdose of pemivibart.

Pemivibart

DB18720

biotech investigational

Deskripsi

Pemivibart (Pemgarda) is a human IgG1 monoclonal antibody targeting the SARS-CoV-2 spike protein receptor binding domain.L50326 It received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain high-risk patient populations.L51733 Due to the amino acid substitutions in the Fc region (M435L/N441A), pemivibart has an extended serum half-life.L51728

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Pemivibart has an extended serum half-life. The half-life was 44.8 days in adults who received a single 4500 IV dose of pemivibart.[L51728]
Volume Distribusi Following the administration of a single 4500 IV dose of pemivibart in adults, the volume of distribution at steady-state was 5.54 (17.0) L.[L51728]
Klirens (Clearance) Following the administration of a single 4500 IV dose of pemivibart in adults, the volume of distribution at steady-state was 0.0909 L/d.[L51728]

Absorpsi

Following the administration of a single 4500 IV dose of pemivibart in adults, the Cmax and AUC0-3 months were 1750 ?g/mL and 36600 days × ?g/mL, respectively.L51728

Metabolisme

Pemivibart is expected to undergo catabolic pathways, in the same manner as endogenous IgG.L51728

Rute Eliminasi

While no information is available, pemivibart is unlikely to undergo renal excretion.L51728

Interaksi Obat

1 Data
Imlifidase The therapeutic efficacy of Pemivibart can be decreased when used in combination with Imlifidase.

Target Protein

Spike glycoprotein S

Referensi & Sumber

Artikel (PubMed)
  • PMID: 39471458
    Bhimraj A, Falck-Ytter Y, Kim AY, Li JZ, Baden LR, Johnson S, Shafer RW, Shoham S, Tebas P, Bedimo R, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Martin GS, MacBrayne C, Nadig N, Nakamura MM, Shumaker AH, Tien P, Loveless J, Morgan RL, Gandhi RT: 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clin Infect Dis. 2024 Oct 29:ciae435. doi: 10.1093/cid/ciae435.
  • PMID: 32762417
    Dehury B, Raina V, Misra N, Suar M: Effect of mutation on structure, function and dynamics of receptor binding domain of human SARS-CoV-2 with host cell receptor ACE2: a molecular dynamics simulations study. J Biomol Struct Dyn. 2021 Nov;39(18):7231-7245. doi: 10.1080/07391102.2020.1802348. Epub 2020 Aug 7.
  • PMID: 35787481
    Verma S, Patil VM, Gupta MK: Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein. Drug Discov Today. 2022 Oct;27(10):103312. doi: 10.1016/j.drudis.2022.06.012. Epub 2022 Jul 3.

Contoh Produk & Brand

Produk: 1 • International brands: 0
Produk
  • Pemgarda
    Injection • 125 mg/1mL • Intravenous • US

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul